Michela Viltadi

Three novel patient‐derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors

Sara Redaelli, Luca Mologni, Roberta Rostagno et al. · American Journal of Hematology · 2012 · 111 citations

Medicine, Oncology, Pharmacology +13

<i>De novo UBE2A</i> mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Vera Magistroni, Mario Mauri, Deborah D’Aliberti et al. · Haematologica · 2019 · 30 citations · Full text

Medicine, Molecular Biology, Oncology +13

ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells

Vera Magistroni, Luca Mologni, Stefano Sanselicio et al. · PLoS ONE · 2011 · 29 citations · Full text

Medicine, Molecular Biology, Oncology +17

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells

Luca Mologni, Mariantonia Costanza, Geeta G. Sharma et al. · Neoplasia · 2018 · 23 citations · Full text

Medicine, Molecular Biology, Oncology +17

Design, Synthesis, and Biological Activity of Urea Derivatives as Anaplastic Lymphoma Kinase Inhibitors

Gustav Boije af Gennäs, Luca Mologni, Shaheen Ahmed et al. · ChemMedChem · 2011 · 22 citations

Medicine, Oncology, Pharmacology +17